366 related articles for article (PubMed ID: 29327913)
1. Proteomic Analysis of the Downstream Signaling Network of PARP1.
Zhen Y; Yu Y
Biochemistry; 2018 Jan; 57(4):429-440. PubMed ID: 29327913
[TBL] [Abstract][Full Text] [Related]
2. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
4. The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
Ke Y; Wang C; Zhang J; Zhong X; Wang R; Zeng X; Ba X
Cells; 2019 Sep; 8(9):. PubMed ID: 31500199
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
Alemasova EE; Lavrik OI
Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
[TBL] [Abstract][Full Text] [Related]
6. The Promise of Proteomics for the Study of ADP-Ribosylation.
Daniels CM; Ong SE; Leung AK
Mol Cell; 2015 Jun; 58(6):911-24. PubMed ID: 26091340
[TBL] [Abstract][Full Text] [Related]
7. Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress.
Hegedűs C; Virág L
Redox Biol; 2014; 2():978-82. PubMed ID: 25460733
[TBL] [Abstract][Full Text] [Related]
8. Mammalian N1-adenosine PARylation is a reversible DNA modification.
Musheev MU; Schomacher L; Basu A; Han D; Krebs L; Scholz C; Niehrs C
Nat Commun; 2022 Oct; 13(1):6138. PubMed ID: 36253381
[TBL] [Abstract][Full Text] [Related]
9. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].
Wiśnik E; Ryksa M; Koter-Michalak M
Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104
[TBL] [Abstract][Full Text] [Related]
10. Cell Cycle Resolved Measurements of Poly(ADP-Ribose) Formation and DNA Damage Signaling by Quantitative Image-Based Cytometry.
Michelena J; Altmeyer M
Methods Mol Biol; 2017; 1608():57-68. PubMed ID: 28695503
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose): PARadigms and PARadoxes.
Bürkle A; Virág L
Mol Aspects Med; 2013 Dec; 34(6):1046-65. PubMed ID: 23290998
[TBL] [Abstract][Full Text] [Related]
12. The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Zhao Y; Zhang LX; Jiang T; Long J; Ma ZY; Lu AP; Cheng Y; Cao DS
Eur J Med Chem; 2020 Oct; 203():112570. PubMed ID: 32717529
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
14. Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry.
Li P; Zhen Y; Yu Y
Methods Enzymol; 2019; 626():301-321. PubMed ID: 31606080
[TBL] [Abstract][Full Text] [Related]
15. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
16. The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers.
Kamaletdinova T; Fanaei-Kahrani Z; Wang ZQ
Cells; 2019 Dec; 8(12):. PubMed ID: 31842403
[TBL] [Abstract][Full Text] [Related]
17. Avoid the trap: Targeting PARP1 beyond human malignancy.
Kim C; Chen C; Yu Y
Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
19. Functions of PARylation in DNA Damage Repair Pathways.
Wei H; Yu X
Genomics Proteomics Bioinformatics; 2016 Jun; 14(3):131-139. PubMed ID: 27240471
[TBL] [Abstract][Full Text] [Related]
20. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
